Blackstone (NYSE: BX), the world’s largest alternative asset manager, is expanding its presence in the life sciences sector with a new multibillion-dollar fund dedicated to drug development.

Rentschler Biopharma is moving away from cell and gene therapy as part of a strategic realignment, opting to focus more on ...

The European Commission (EC) has authorized the combination of ViiV Healthcare’s Vocabria (cabotegravir long-acting ...

As of today, all clinical trials in the European Union (EU), including those that were approved under the previous legal framework, the Clinical Trials Directive (CTD), are governed by the Clinical ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is ...